Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin).
HCV
daclatasvir
hypothyroidism
peg-IFN-α
ribavirin
sofosbuvir
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
revised:
15
04
2020
received:
13
02
2020
accepted:
16
04
2020
medline:
19
5
2020
pubmed:
19
5
2020
entrez:
19
5
2020
Statut:
ppublish
Résumé
The recent development of direct-acting antiviral (DAA) drugs has revolutionized the area of hepatitis C virus (HCV) therapeutics but the efficacy and clinical outcome of interferon (IFN)-free therapy have not been extensively studied yet. We observed a dramatic increase in hypothyroidism among patients treated with sofosbuvir, IFN, and ribavirin. This is the first prospective study of the thyroid dysfunction in DAA drugs treated patients. This study compared the risk of hypothyroidism in two different groups of HCV patients treated with different DAA drugs regimens that were sofosbuvir + pegylated-IFN-α + ribavirin and sofosbuvir + daclatasvir + ribavirin. Our findings highlight the periodic screening of serum thyroid-stimulating hormone and T4 levels in HCV infected patients during the treatment and posttreatment.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3868-3870Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Wahid B, Waqar M, Rasool N, et al. Recent trends in molecular epidemiology of hepatitis C virus in Mardan, KPK Pakistan. Infect Genet Evol. 2018;66:66-71.
Pastore F. Hepatitis C virus infection and thyroid autoimmune disorders: a model of interactions between the host and the environment. World J Hepatol. 2016;8(2):83-91.
Mao XR, Zhang LT, Chen H, Xiao P, Zhang YC. Possible factors affecting thyroid dysfunction in hepatitis C virus-infected untreated patients. Exp Ther Med. 2014;8(1):133-140.
Batool N, Elahi S, Saleem N, Ashraf A. Thyroid dysfunction in non-interferon treated hepatitis C patients residing in the hepatitis endemic area. BioMed Res Int. 2017;2017:2390812.
Andrade LJ, Atta AM, D'Almeida Junior A, Paraná R. Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin: a review. Braz J Infect Dis. 2008;12(2):144-148.
Goyal G, Panag K, Garg R. Prevalence of thyroid disorders in hepatitis C virus-positive patients on interferon and antiviral therapy. Int J Appl Basic Med Res. 2016;6(4):245-248.
Wahid B, Waqar M, Rasool N, Wasim M, Khalid I, Idrees M. Prevalence of thyroid-stimulating hormone dysfunction among sofosbuvir-treated HCV-infected patients: a real-world clinical experience. J Med Virol. 2019;91(3):514-517.
Abbas Z, Saad M, Nadeem R, Jawed F, Abbas M. Sofosbuvir and ribavirin with or without pegylated interferon for hepatitis C genotype 3: a real-world experience. Hepat Mon. 2017;17(4):e12297.
Chang Y-K, Tseng YT, Chen KH, Chen KT. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan. BMC Endocr Disord. 2019;19(1):36.
Jadali Z. Autoimmune thyroid disorders in hepatitis C virus infection: effect of interferon therapy. Indian J Endocrinol Metab. 2013;17(1):69.